MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.dld.2020.12.120

Медицинская библиотека · Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver · 2021

Impact of the COVID-19 outbreak and the serum prevalence of SARS-CoV-2 antibodies in patients with inflammatory bowel disease treated with biologic drugs.

Bossa Fabrizio, Carparelli Sonia, Latiano Anna, Palmieri Orazio, Tavano Francesca, Panza Anna, Pastore Maria, Marseglia Antonio, D'Altilia Mario, Latiano Tiziana, Corritore Giuseppe, Martino Giuseppina, Nardella Marianna, Guerra Maria, Terracciano Fulvia, Sacco Michele, Perri Francesco, Andriulli Angelo

СтатьяПеревод в очереди

Аннотация

BACKGROUND

Patients receiving biologic therapies are at risk for viral infections. This study investigated the impact of the SARS-CoV-2 infection and the serum prevalence of SARS-CoV-2 antibodies in patients with inflammatory bowel disease (IBD) treated with biologic drugs.

METHODS

Information on demography, co-morbidities, clinical data regarding IBD, symptoms suggestive of the SARS-CoV-2 infection, close contacts with SARS-CoV-2 positive patients, hospitalization, and therapies administered for COVID-19 was collected for all patients who were being treated with biologic drugs. All patients underwent SARS-CoV-2 antibody testing.

RESULTS

Two hundred and fifty-nine patients (27 children) with a mean age of 42.2 ± 16.7 years (range 9 - 88) and a mean duration of disease of 13.4 ± 10 years (range 0.2 - 49) were enrolled. One hundred four patients (40.2%) had ulcerative colitis, and 155 (59.8%) had Crohn's disease. About the therapy: 62 patients were receiving infliximab, 89 adalimumab, 20 golimumab, 57 vedolizumab, 27 ustekinumab, 1 thalidomide, and 3 an experimental compound. The mean Charlson Comorbidity Index was 2. Thirty-two patients (12.3%) reported respiratory symptoms, and 2 of them were hospitalized (0.77%). Two patients resulted positive for IgG against SARS-CoV-2 (0.77%).

CONCLUSIONS

In patients with IBD, treatment with biologic drug does not represent a risk factor for the SARS-CoV-2 infection.

Для цитирования: Bossa Fabrizio, Carparelli Sonia, Latiano Anna, Palmieri Orazio, Tavano Francesca, Panza Anna, Pastore Maria, Marseglia Antonio, D'Altilia Mario, Latiano Tiziana, Corritore Giuseppe, Martino Giuseppina, Nardella Marianna, Guerra Maria, Terracciano Fulvia, Sacco Michele, Perri Francesco, Andriulli Angelo. Impact of the COVID-19 outbreak and the serum prevalence of SARS-CoV-2 antibodies in patients with inflammatory bowel disease treated with biologic drugs.. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver. 2021. DOI: 10.1016/j.dld.2020.12.120.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.